Cardiac
-
Abbott starts trial of Encantor transcatheter aortic valve
The balloon-expandable system could complement Abbott’s existing self-expanding Navitor device.
By Nick Paul Taylor • Nov. 20, 2026 -
Remedy Robotics raises $62M; Capstan’s mitral replacement robot progresses
Remedy plans a pivotal trial and has its sights on bringing to market a system for neurovascular intervention, while Capstan Medical performed the first U.S. transcatheter mitral valve replacement with its investigational robot.
By Susan Kelly • Nov. 18, 2026 -
Explore the Trendline➔
Courtesy of Johnson & Johnson
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
Abbott’s defibrillation lead lands FDA approval and CE mark
The authorizations position Abbott to launch a purpose-built lead for left bundle branch area pacing in the U.S. and Europe.
By Nick Paul Taylor • Nov. 12, 2026 -
Getinge hires president of acute care therapies
Stacy Beske joins Getinge from Philips and will take over the role on Dec. 1.
By Nick Paul Taylor • Nov. 10, 2026 -
Edwards bumps up sales forecast on TAVR strength in Q3
Going forward, the heart valve maker expects procedure volumes to rise following positive study data and expanded Medicare reimbursement.
By Susan Kelly • Nov. 5, 2026 -
Boston Scientific, Blackstone agree to $455M deal to co-fund heart pump development
As part of the agreement, Blackstone may receive regulatory and commercial milestone payments, plus royalties on net sales.
By Nick Paul Taylor • Nov. 5, 2026 -
3 takeaways from TCT 2026
Edwards’ TAVR results in moderate aortic stenosis drew applause from meeting attendees, while Medtronic’s renal denervation and Abbott’s left atrial appendage closure devices also produced positive study findings.
By Susan Kelly • Nov. 4, 2026 -
Abbott starts pivotal trial for mitral valve replacement device
The study is testing a device that Abbott executives believe can expand the mitral valve market.
By Nick Paul Taylor • Nov. 2, 2026 -
Abbott grows cardiac portfolio with Amplatzer approval for valve leaks
The first-of-its-kind transcatheter device treats paravalvular leak after valve replacement surgery, to spare the patient from another open-heart surgery.
By Susan Kelly • Oct. 29, 2026 -
Edwards wins FDA approval for tricuspid valve repair device
Edwards’ approval should “strengthen the company’s position in the large and underpenetrated transcatheter tricuspid market,” analysts said.
By Nick Paul Taylor • Oct. 23, 2026 -
Medtronic wins CE mark for Vitalis portfolio of cardiac pacemakers
The CE mark clears Medtronic to sell conduction system pacing therapy devices in Europe.
By Nick Paul Taylor • Oct. 20, 2026 -
Edwards recall of Sapien mitral delivery systems tied to 1 death
Edwards is asking customers to return some of the delivery systems used with its Sapien M3 devices after receiving three reports of balloons bursting when inflated during the procedure.
By Susan Kelly • Oct. 16, 2026 -
Boston Scientific names Joseph Fitzgerald as chief operating officer
Fitzgerald will oversee three newly established reportable segments as Boston Scientific works to bounce back from guidance cuts.
By Nick Paul Taylor • Oct. 8, 2026 -
Medtronic names Felicia Kurz as cardiac ablation VP, GM
Kurz’s appointment comes as Medtronic enjoys strong growth in electrophysiology therapies thanks to demand for its pulsed field ablation devices.
By Susan Kelly • Oct. 7, 2026 -
Abbott gets FDA nod for updates to heart failure monitoring system
Patients can view their pulmonary artery pressure readings on their phone with the CardioMEMS updates, giving them a more active role in their care.
By Elise Reuter • Oct. 7, 2026 -
ARPA-H awards more than $100M to biosensor development projects
Four organizations will develop devices for tracking heart disease, inflammation and perimenopause.
By Nick Paul Taylor • Oct. 5, 2026 -
Retrieved from Michigan Medicine on October 02, 2026
Edwards’ adjustable heart valve for children lands FDA approval
The device could help young patients avoid multiple open-heart surgeries as they grow, FDA officials said.
By Susan Kelly • Oct. 2, 2026 -
Medtronic reveals cardiac mapping and ablation software clearances
The regulatory authorizations come as Medtronic looks to differentiate itself in the fast-growing pulsed field ablation market targeted by rivals Abbott, Boston Scientific and J&J.
By Nick Paul Taylor • Oct. 1, 2026 -
Intuitive expands push into cardiac market with CE mark
After de-emphasizing heart surgery for decades due to limits with its earlier platforms, the surgical robot maker is eyeing the large market in cardiovascular disease treatment.
By Susan Kelly • Sept. 25, 2026 -
CVRx names John Landry as CFO
Landry joins in the aftermath of an investor’s call for the sale of the heart failure device company.
By Nick Paul Taylor • Sept. 23, 2026 -
Cordis wins FDA approval for sirolimus-eluting balloon
The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
By Nick Paul Taylor • Sept. 22, 2026 -
Recor Medical ex-CEO Lara Barghout joins Medtronic
Barghout, who led Recor when it won FDA approval of the first renal denervation treatment for hypertension, is the new president of Medtronic’s Interventional Cardiology Therapies business.
By Susan Kelly • Sept. 16, 2026 -
J&J sells Laminar LAA closure assets it bought 3 years ago
The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.
By Susan Kelly • Sept. 16, 2026 -
CMS expands TAVR Medicare coverage to asymptomatic patients
The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.
By Susan Kelly • Sept. 11, 2026 -
ARPA-H to award $62.7M for AI in cardiovascular care
Companies including Tempus AI and Updoc are tasked with building an agentic AI system for managing heart failure.
By Elise Reuter • Sept. 11, 2026